0.22p
+3.35%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Futura Medical
Its shares trade on LSE under the ticker FUM.L. It has been listed since 10 July 2006. In the fiscal year to 31 December 2024, it reported revenue of £13.9m and net income of £1.3m. At that date it held total assets of £13.6m and shareholders' equity of £9.0m.
Futura Medical Plc is a pharmaceutical group that develops products for both the prescription and consumer healthcare markets. The company is headquartered in Guildford, Surrey. The company went IPO on 2006-07-10. The firm is engaged in the research and development of pharmaceutical drugs and medical devices and the commercial exploitation. The company is also engaged in transdermal delivery and has developed a transdermal technology, DermaSys for the absorption of active molecules through the skin. The company specializes in sexual health and pain relief, and has approximately five products in its development pipeline, which include CSD500, MED2002, TPR100, TIB200 and SPR300. Its CSD500 product incorporates an erectogenic gel (known as Zanifil gel) to help men maintain a firmer erection during intercourse whilst wearing a condom. Its MED2002 is a gel applied directly to the penis for the treatment of male erectile dysfunction (ED). The firm's TPR100 is a gel to provide pain relief. Its SPR300 is a gel, which combines methyl salicylate and menthol with the DermaSys delivery system.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 Jul 2006
- Employees
- 13
- Website
- futuramedical.com ↗
Leadership
Pay as last reported
- Mr. Alexander DugganInterim Chief Executive Officer
- Ms. Angela HildrethFinance Director, Chief Operating Officer, Company Secretary, Executive Director, since 2018£383,887
- Mr. Ken JamesExecutive Director, Head of R&D, since 2016£351,120
- Mr. Harmesh SuniaraNon-Executive Director
- Mr. Gordon DavisIndependent Non-Executive Director£54,600
- Mr. Andrew UnittSenior Non-Executive Independent Director£54,600
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Futura Medical PLC has several strengths that contribute to its success in the market. Firstly, the company has a strong portfolio of innovative healthcare products, including advanced medical devices and pharmaceuticals. This diverse range allows Futura Medical to cater to various customer needs and address different market segments.
- Secondly, Futura Medical has a robust research and development team, constantly working on new products and advancements. This steady stream of innovation ensures that the company remains at the forefront of medical technology, fostering a competitive edge.
- Furthermore, Futura Medical has established strategic partnerships with key industry players and healthcare professionals. These partnerships provide access to valuable resources, expertise, and distribution channels, aiding in the successful launch and commercialization of their products.
Weaknesses
- Despite its strengths, Futura Medical also faces certain weaknesses that need to be addressed. One notable weakness is the company's relatively small scale compared to some of its competitors. This may limit their financial resources and ability to invest heavily in marketing or research and development.
- Additionally, Futura Medical's success heavily relies on the regulatory approval of its products. Delays or rejections in the approval process can significantly impact their revenue and profitability. It is important for the company to proactively manage this risk and ensure efficient regulatory procedures.
Opportunities
- Futura Medical operates in a dynamic and evolving healthcare industry, presenting several opportunities for growth. The increasing demand for advanced medical solutions, driven by aging populations and rising healthcare expenditure, creates a favorable market environment for the company.
- Moreover, the expansion into new geographic regions and emerging markets provides Futura Medical with untapped growth potential. By strategically targeting these markets, the company can diversify its revenue streams and reduce dependence on specific regions.
- Additionally, the ongoing advancements in medical technology and increased awareness of health and wellness offer opportunities for Futura Medical to develop innovative products that address unmet medical needs and cater to evolving consumer preferences.
Threats
- Futura Medical faces certain threats in the market that must be carefully managed. One significant threat is intense competition from rival companies operating within the healthcare industry. This competition may result in pricing pressures, reduced market share, or difficulties in gaining product differentiation.
- Furthermore, changes in regulatory policies and stringent compliance requirements pose a threat to the company's operations. Adapting to evolving regulations and maintaining compliance can be time-consuming and costly for Futura Medical, affecting their ability to efficiently bring new products to market.
- Another threat is the potential risk of intellectual property infringement. Protecting their proprietary technology and patents is crucial for Futura Medical to safeguard their competitive advantage and prevent unauthorized use by competitors.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.